Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users

Back to Search
Print
Bookmark Trial

NCT00977249

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Gentofte Hospital
Copenhagen, Hellerup, 2900, Denmark
See other locations
Contact
+4539773508
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

+4539773508

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Tobacco Dependence
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Long-term, daily NRT users (except nicotine patch) (>11 months) ex-smokers that are willing to try to stop the use of NRT and adhere to this protocol.

- More than 4 pieces of nicotine gum/ sublingual tablets/ lozenges/ per day, OR more than 3 inhaler cylinders per day, OR

- more than 10 puffs of nasal spray per day.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Age < 18 years,


- CO Smokers,


- Pregnant and lactating women,


- Used varenicline before,


- Not able to cooperate,


- Other significant diseases that might influence the trial (such as moderate -severe
cardiac disease, lung cancer,) in expired air > 7 ppm.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Tobacco DependenceVarenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement
NCT00747643
  1. Tampa, Florida
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Tobacco DependenceVarenicline for Long-term Nicotine Replacement Therapy (NRT) Users
NCT00977249
  1. Copenhagen, Hellerup
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users
Official Title  ICMJE Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users. A Double Blind, Placebo Controlled Trial
Brief Summary

Primary aim: Will varenicline be better than placebo to get long-term users of NRT to stop?

Secondary aim: To assess in details some side effects of varenicline i.e. nausea and abnormal dreams.

Detailed Description

100-200 long-term users of NRT will be enrolled in a placebo, controlled, randomized trial with varenicline or placebo for 12 weeks to stop the use of NRT.

Assessments consist of carbon monoxide in expired air, p-cotinine, body-weight, questions about craving, nausea and dreams. Primary result is percent not using NRT and not smoking at 12 weeks (point prevalence last 7 days) and secondary result is not smoking and not using NRT at 12 months. Secondary aims, is a more detailed assessment of nausea and dreams; well-known side effects of varenicline and secondary results are a qualitative description of nausea and dreams.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Tobacco Dependence
Intervention  ICMJE
  • Behavioral: support and visits
    visits at weeks 0,2,4,6,9 and 12 and 12 months
  • Drug: varenicline
  • Drug: placebo
Study Arms  ICMJE
  • Active Comparator: varenicline

    Varenicline for 12 weeks.

    The treatment schedule for varenicline is:

    Varenicline tablets, 0.5 mg x 1 daily, day 1-3 Varenicline 0.5 mg x 2, day 4-6 Varenicline 1 mg x 2, day 7 up to 12 weeks

    Interventions:
    • Behavioral: support and visits
    • Drug: varenicline
  • Placebo Comparator: placebo
    Placebo for 12 weeks
    Interventions:
    • Behavioral: support and visits
    • Drug: placebo
Publications * Tønnesen P, Mikkelsen K. Varenicline to stop long-term nicotine replacement use: a double-blind, randomized, placebo-controlled trial. Nicotine Tob Res. 2013 Feb;15(2):419-27. doi: 10.1093/ntr/nts146. Epub 2012 Sep 27.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Unknown status
Estimated Enrollment  ICMJE
 (submitted: September 14, 2009)		200
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 2011
Estimated Primary Completion Date December 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Long-term, daily NRT users (except nicotine patch) (>11 months) ex-smokers that are willing to try to stop the use of NRT and adhere to this protocol.
  • More than 4 pieces of nicotine gum/ sublingual tablets/ lozenges/ per day, OR more than 3 inhaler cylinders per day, OR
  • more than 10 puffs of nasal spray per day.

Exclusion Criteria:

  • Age < 18 years,
  • CO Smokers,
  • Pregnant and lactating women,
  • Used varenicline before,
  • Not able to cooperate,
  • Other significant diseases that might influence the trial (such as moderate -severe cardiac disease, lung cancer,) in expired air > 7 ppm.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Denmark
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00977249
Other Study ID Numbers  ICMJE EudraCTnumber 2008-006426-24
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Chief Physician Philip Tønnesen, M.D., Gentofte University Hospital
Study Sponsor  ICMJE University Hospital, Gentofte, Copenhagen
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Principal Investigator:Philip Tønnesen, M.D.Gentofte Hospital
PRS Account University Hospital, Gentofte, Copenhagen
Verification Date September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP